Document Detail

Serum soluble interleukin 2 receptor in hemodialysis patients treated with recombinant human erythropoietin.
MedLine Citation:
PMID:  8821199     Owner:  NLM     Status:  MEDLINE    
The cell-mediated immunity was studied in 14 hemodialysis patients by determination of the serum levels of soluble interleukin 2 receptor (sIL-2R) before (hemoglobin 7.9 +/- 0.6 g/dl) and after 16 months of recombinant human erythropoietin (rHuEPO) administration (hemoglobin 10.3 +/- 1.1 g/dl) and compared with 14 hemodialysis patients not receiving the drug (hemoglobin 9.7 +/- 1.4 g/dl). The sIL-2R level was higher in severely anemic patients starting rHuEPO than in patients not receiving the drug (9,414 +/- 2,822 vs. 5,001 +/- 2,905 pg/ml; p < 0.05). At the end of the 16-month observation period, a decrease in sIL-2R of about 48% was observed following raising hemoglobin with rHuEPO, whereas untreated patients exhibited a further increase in sIL-2R, amounting to 59% (p < 0.001). There was a correlation between sIL-2R and hemoglobin (r = -0.40; p < 0.02) at the start of the study and between sIL-2R and hemoglobin (r = -0.43; p < 0.02) and monocyte number (r = 0.48; p < 0.01) at the end of the observation period. Elevated serum sIL-2R levels, a characteristic finding of the altered cell-mediated immunity of hemodialysis patients, may be influenced by the increase in hemoglobin concentration following rHuEPO administration rather than by the hormone itself.
J J Sennesael; C G Demanet; D L Verbeelen
Related Documents :
3792059 - Life-threatening theophylline toxicity is not predictable by serum levels.
6690999 - Elevated circulating levels of eosinophil cationic protein in uremia as signs of abnorm...
19758299 - Variability in calcium, phosphorus, and parathyroid hormone in patients on hemodialysis.
21075579 - Life-threatening hyperkalemia from nutritional supplements: uncommon or undiagnosed?
20609189 - Impact of serum apolipoprotein a-iv as a marker of cardiovascular disease in maintenanc...
19073379 - Associated risk factors for abnormal ankle-brachial index in hemodialysis patients in a...
2964459 - Lymphomatoid papulosis and its relationship to "idiopathic" hypereosinophilic syndrome.
15543329 - Over-the-counter vitamin k1-containing multivitamin supplements disrupt warfarin antico...
14614709 - Effects of the herbal medicine inchinko-to on liver function in postoperative patients ...
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Blood purification     Volume:  13     ISSN:  0253-5068     ISO Abbreviation:  Blood Purif.     Publication Date:    1995 Nov-Dec
Date Detail:
Created Date:  1996-12-11     Completed Date:  1996-12-11     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8402040     Medline TA:  Blood Purif     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  347-56     Citation Subset:  IM    
Renal Unit, Akademisch Ziekenhuis, Vrije Universiteit, Brussel, Belgium.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anemia / blood,  drug therapy,  immunology
Blood Urea Nitrogen
Creatinine / blood
Erythropoietin / therapeutic use*
Follow-Up Studies
Hemoglobins / analysis
Immunity, Cellular*
Kidney Failure, Chronic / blood,  immunology,  therapy
Middle Aged
Parathyroid Hormone / blood
Receptors, Interleukin-2 / analysis*
Recombinant Proteins / therapeutic use
Renal Dialysis*
Reg. No./Substance:
0/Hemoglobins; 0/Parathyroid Hormone; 0/Receptors, Interleukin-2; 0/Recombinant Proteins; 11096-26-7/Erythropoietin; 60-27-5/Creatinine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pharmacokinetics of zidovudine in HIV-infected patients with end-stage renal disease.
Next Document:  Metabolic acidosis and nutrition in dialysis patients.